[Pleuropneumopathy caused by bromocriptine in a patient with Parkinson disease. Review of the literature apropos of a new case].
Bromocriptine, a derivate of ergot of rye, is employed in high doses for the treatment of Parkinson's disease, and may induct pleuropulmonary affections. We report the case of a 75-years-old patient, on bromocriptin for 5 years, who presented a progressive dyspnea, due to a pleural thickening, and moderate interstitial infiltrate, associated with an inflammatory syndrome. The outcome was favorable with 3 months of bromocriptin cessation. These complications are rarely described, probably underestimated, and justify a respiratory follow-up for these patients, who are difficult to stabilize in their neurologic treatment.
Debove
P
P
Service de Pneumologie, Hôpital d'Instruction des Armées Percy, 101, avenue Henri-Barbusse, 92141 Clamart.
Simon
F
F
Vaylet
F
F
Renard
J L
JL
L'Her
P
P
D000368:Aged; D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001971:Bromocriptine / Q000008:administration & dosage / Q000009:adverse effects*; D003937:Diagnosis, Differential; D004305:Dose-Response Relationship, Drug; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D010300:Parkinson Disease / Q000188:drug therapy*; D011001:Pleuropneumonia / Q000139:chemically induced* / Q000000981:diagnostic imaging; D011658:Pulmonary Fibrosis / Q000139:chemically induced* / Q000000981:diagnostic imaging; D014057:Tomography, X-Ray Computed
D000978:Antiparkinson Agents; D001971:Bromocriptine